Chan (2003)
Hong Kong
N = 77; Paediatric
|
ALT + AST – 59.2%
Bilirubin – 5.6%
|
5.7 weeks
|
Gonzalez Sandana (2012)
Mexico
N = 163; Paediatric
|
Transaminases – 40.0%
Bilirubin – 42.1%
|
NR
|
Herbinger (2016)
Germany
N = 51; All ages
|
AST – 64.7%
ALT – 76.5%
GGT – 70.6%
|
NR
|
Ishibashi (1987)
Japan
N = 9; Adult
|
Transaminases – 100%
|
NR
|
Massei (2001)
Italy
N = 54; All ages
|
ALT – 48.1%
GGT – 20.4%
|
12 weeks
|
Mazur (2019)
Poland
N = 181; Paediatric
|
AST – 48.1%
ALT – 49.2%
GGT – 26.5%
|
NR
|
Monteiro (2020)
Brazil
N = 251; All ages
|
AST – 11.8%
ALT – 15.8%
GGT – 25.0%
|
NR
|
Mygind (1976)
Denmark
N = 36; Ages not specified
|
AST – 69.4%
|
10 weeks
|
Rotenburg (1991)
Israel
N = 82; Ages not specified
|
AST – 69.5%
ALT – 89.0%
|
NR
|
Sohn (2017)
Korea
N = 149; Paediatric
|
ALT – 71.1%
|
NR
|
Son (2011)
Korea
N = 81; Paediatric
|
ALT +/- AST – 51.9%
|
NR
|
Sridhar (2018)
Hong Kong
N = 25; Adult
|
AST – 100.0%
ALT – 96.0%
GGT – 91.7%
ALP – 56.0%
Bilirubin – 0%
|
NR
|
Vanderhorst (1991)
USA
N = 120; Ages not specified
|
AST – 43.1%
ALT – 40.5%
|
NR
|
Zhang (2017)
China
N = 95; Ages not specified
|
No numerical values but ‘ALT, AST and GGT levels are significantly
increased in IM patients compared to controls’; ‘bilirubin is lower
compared to controls’
|
NR
|
Gadeberg (1984)
Denmark
N = 10; All ages
|
ALT – 88.9%
|
>6 weeks
|
Dommerby (1986)
Denmark
N = 29; All ages
|
AST – 65.6%
ALP – 31.0%
Bilirubin – 0.0%
|
17 weeks
|
Baehner (1967)
USA
N = 105; Paediatrics
|
AST – 24.4%
ALT – 35.6%
Bilirubin – 15.6%
|
NR
|
Kanegane (1997)
Japan
N = 54; Paediatrics
|
No numerical values but ‘mean AST and ALT values for all study patients
were abnormal’
|
NR
|
Henke (1973)
USA
N = 776; All ages
|
Liver function – 53.8%
|
NR
|
Rosalki (1960)
UK
N = 23; Adult
|
AST – 78.3%
ALT – 82.6%
ALP – 39.1%
Bilirubin – 13.0%
|
12 weeks
|
Shuster (1967)
USA
N = 46; Ages not specified
|
AST – 83.7%
ALP – 82.6%
Bilirubin – 17.8%
|
NR
|
Kilpatrick (1966)
Germany
N = 20; Adult
|
ALT – 65.0%
ALP – 38.9%
Bilirubin – 6.7%
|
NR
|
Grotto (2003)
Israel
N = 114; Adult
|
AST – 34.7%
ALT – 53.2%
Bilirubin – 14.9%
|
NR
|
Gao (2011)
China
N = 418; Paediatric
|
AST + ALT – 48.6%
|
NR
|
Rea (2001)
USA
N = 140; All ages
|
AST – 31.4%
ALT – 61.4%
Bilirubin – 5.7%
|
>6 months
|
Ginsburg (1977)
USA
N = 30; Paediatric
|
AST – 36.7%
Bilirubin – 10.0%
|
NR
|
Gelb (1962)
USA
N = 69; All ages
|
AST – 83.0%
ALT – 84.1%
ALP – 81.4%
Bilirubin – 42.9%
|
6 weeks
|
Finkel (1964)
USA
N = 235; Ages not specified
|
AST – 78.0%
ALT – 78.6%
ALP – 76.3%
Bilirubin – 21.1%
|
NR
|
Wang (2013)
China
N = 287; All ages
|
AST – 74.1%
ALT – 74.7%
GGT – 52.8%
Bilirubin – 12.6%
|
>12 days
|
Topp (2015)
Denmark
N = 95; Paediatric
|
ALT – 53.7%
Bilirubin – 9.3%
|
NR
|
Baron (1965)
UK
N = 80; Ages not specified
|
AST – 72.5%
ALP – 55.2%
Bilirubin – 37.7%
|
6 weeks
|
Evans (1948)
USA
N = 19; Ages not specified
|
ALP – 42.9%
Bilirubin – 36.8%
|
>6 weeks
|
NR – Not reported |
NR – Not reported |
NR – Not
reported |